Molecularly imprinted nanoparticles as drug carriers to the brain
Source abstract
Abstract
Molecularly imprinted polymers (MIPs) have a high potential for use as drug delivery carriers. These materials exhibit beneficial properties such as stability, low toxicity, biodegradability, and the ability to form specific binding sites. New systems capable of crossing the blood–brain barrier (BBB) are important for the development of new treatments for nervous central system diseases. Due to the presence of apolipoprotein E (ApoE) receptors in the BBB, some nanomaterials functionalized with ApoE may be efficient systems for the drug delivery in the brain. In this way, a nano-MIP conjugated with ApoE (MIP-ApoE) was synthesized, characterized and evaluated as a possible drug nanocarrier to the brain. A non-imprinted polymer (NIPs) and a NIP conjugated with ApoE (NIP-ApoE) were also synthesized and compared with MIP and MIP-ApoE. The nanoparticles were loaded with donepezil (drug used for a proof-of-principle study), and the formulations were tested for cytocompatibility, in vitro release, and permeability through BBB model using hCMEC/D3 cells. Free donepezil, donepezil-loaded nanoparticles, and unloaded nanoparticles had a hemolytic activity lower than 15% and cell viability greater than 70%. The quantified donepezil in the plasma samples of animals treated with MIP and MIP-ApoE supported the in vitro results of sustainable donepezil release by these nanoparticles. When the nanoparticles were functionalized with ApoE, the permeability in the hCMEC/D3 monolayer increased (1.9 times). The brain samples of animals treated with MIP-ApoE had a slightly lower concentration of donepezil than the MIP treatment. One possible explanation is that, only the MIP-ApoE, with part of the donepezil complexed at its binding sites, can penetrate the brain. As a result, a reduced amount of donepezil remains free to be quantified.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Pharmacological Effects and Toxicity Studies · Analytical chemistry methods development · Epilepsy research and treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human health care. Nanomedicine 3:20–31. https://doi.org/10.1016/j.nano.2006.11.00810.1016/j.nano.2006.11.008 ↗
2. Martins SM, Sarmento B, Nunes C et al (2013) Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm 85:488–502. https://doi.org/10.1016/j.ejpb.2013.08.01110.1016/j.ejpb.2013.08.011 ↗
3. Lu W, Zhang Y, Tan Y-Z et al (2005) Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 107:428–448. https://doi.org/10.1016/j.jconrel.2005.03.02710.1016/j.jconrel.2005.03.027 ↗
4. Neves AR, Queiroz JF, Lima SAC, Reis S (2017) Apo E-functionalization of solid lipid nanoparticles enhances brain drug delivery: uptake mechanism and transport pathways. Bioconjug Chem 28:995–1004. https://doi.org/10.1021/acs.bioconjchem.6b0070510.1021/acs.bioconjchem.6b00705 ↗
5. Hu K, Li J, Shen Y et al (2009) Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55–61. https://doi.org/10.1016/j.jconrel.2008.10.01610.1016/j.jconrel.2008.10.016 ↗
6. Neves AR, Queiroz JF, Weksler B et al (2015) Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E. Nanotechnology 26:495103. https://doi.org/10.1088/0957-4484/26/49/49510310.1088/0957-4484/26/49/495103 ↗
7. Siqueira Silva M, Moreira Tavares AP, Leomil Coelho LF et al (2021) Rational selection of hidden epitopes for a molecularly imprinted electrochemical sensor in the recognition of heat-denatured dengue NS1 protein. Biosens Bioelectron 191:113419. https://doi.org/10.1016/j.bios.2021.11341910.1016/j.bios.2021.113419 ↗
8. Silva MS, Tavares APM, de Faria HD et al (2022) Molecularly imprinted solid phase extraction aiding the analysis of disease biomarkers. Crit Rev Anal Chem 52:933–948. https://doi.org/10.1080/10408347.2020.184313110.1080/10408347.2020.1843131 ↗
9. Dias ACBCB, Figueiredo ECC, Grassi V et al (2008) Molecularly imprinted polymer as a solid phase extractor in flow analysis. Talanta 76:988–996. https://doi.org/10.1016/j.talanta.2008.05.04010.1016/j.talanta.2008.05.040 ↗
10. Ruela ALM, de Figueiredo EC, de Araújo MB et al (2016) Molecularly imprinted microparticles in lipid-based formulations for sustained release of donepezil. Eur J Pharm Sci 93:114–122. https://doi.org/10.1016/j.ejps.2016.08.01910.1016/j.ejps.2016.08.019 ↗
11. Luliński P (2017) Molecularly imprinted polymers based drug delivery devices: a way to application in modern pharmacotherapy. A review. Mater Sci Eng C 76:1344–1353. https://doi.org/10.1016/j.msec.2017.02.13810.1016/j.msec.2017.02.138 ↗
12. Hiratani H, Fujiwara A, Tamiya Y et al (2005) Ocular release of timolol from molecularly imprinted soft contact lenses. Biomaterials 26:1293–1298. https://doi.org/10.1016/j.biomaterials.2004.04.03010.1016/j.biomaterials.2004.04.030 ↗
13. Ruela ALM, Figueiredo EC, Pereira GR (2014) Molecularly imprinted polymers as nicotine transdermal delivery systems. Chem Eng J 248:1–8. https://doi.org/10.1016/j.cej.2013.12.10610.1016/j.cej.2013.12.106 ↗
14. Asadi E, Abdouss M, Leblanc RM et al (2016) In vitro/in vivo study of novel anti-cancer, biodegradable cross-linked tannic acid for fabrication of 5-fluorouracil-targeting drug delivery nano-device based on a molecular imprinted polymer. RSC Adv 6:37308–37318. https://doi.org/10.1039/C6RA03704F10.1039/C6RA03704F ↗
15. de Souza IFF, dos Santos TQ, Placido RV et al (2021) The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of Alzheimer’s disease. Colloids Surf B Biointerfaces 203:111721. https://doi.org/10.1016/j.colsurfb.2021.11172110.1016/j.colsurfb.2021.111721 ↗
16. Foo KY, Hameed BH (2010) Insights into the modeling of adsorption isotherm systems. Chem Eng J 156:2–10. https://doi.org/10.1016/j.cej.2009.09.01310.1016/j.cej.2009.09.013 ↗
17. dos Santos RC, Kakazu AK, Santos MG et al (2017) Characterization and application of restricted access carbon nanotubes in online extraction of anticonvulsant drugs from plasma samples followed by liquid chromatography analysis. J Chromatogr B Analyt Technol Biomed Life Sci 1054:50–56. https://doi.org/10.1016/j.jchromb.2017.02.02510.1016/j.jchromb.2017.02.025 ↗
18. Silva FAB, Chagas-Silva FA, Florenzano FH, Pissetti FL (2016) Poly(dimethylsiloxane) and poly[vinyltrimethoxysilane-co-2-(dimethylamino) ethyl methacrylate] based cross-linked oroganic-inorganic hybrid adsorbent for copper(II) removal from aqueous solutions. J Braz Chem Soc 27:2181–2191. https://doi.org/10.5935/0103-5053.2016011010.5935/0103-5053.20160110 ↗
19. Silva SG, Pinheiro M, Pereira R et al (2022) Serine-based surfactants as effective antimicrobial agents against multiresistant bacteria. Biochim et Biophys Acta (BBA) Biomembranes 1864:183969. https://doi.org/10.1016/j.bbamem.2022.18396910.1016/j.bbamem.2022.183969 ↗
20. Neves AR, Queiroz JF, Reis S (2016) Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol 14:27. https://doi.org/10.1186/s12951-016-0177-x10.1186/s12951-016-0177-x ↗
21. Burvin R, Zloczower M, Karnieli E (1998) Double-vein jugular/inferior vena cava clamp technique for long-term in vivo studies in rats. Physiol Behav 63:511–515. https://doi.org/10.1016/S0031-9384(97)00486-110.1016/S0031-9384(97)00486-1 ↗
22. Guo W, Quan P, Fang L et al (2015) Sustained release donepezil loaded PLGA microspheres for injection: preparation, in vitro and in vivo study. Asian J Pharm Sci 10:405–414. https://doi.org/10.1016/j.ajps.2015.06.00110.1016/j.ajps.2015.06.001 ↗
23. Zhang P, Chen L, Gu W et al (2007) In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer’s disease. Biomaterials 28:1882–1888. https://doi.org/10.1016/j.biomaterials.2006.12.01610.1016/j.biomaterials.2006.12.016 ↗
24. Silverstein RM, Webster FX, Kiemle DJ, Chapman OL (2005) Spectrometric identification of organic compounds. J Am Chem Soc 85:3316–3316. https://doi.org/10.1021/ja00903a07710.1021/ja00903a077 ↗
25. Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1–9. https://doi.org/10.1016/j.ejpb.2007.08.00110.1016/j.ejpb.2007.08.001 ↗
26. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318
27. Mizuguchi C, Hata M, Dhanasekaran P et al (2014) Fluorescence study of domain structure and lipid interaction of human apolipoproteins E3 and E4. Biochim et Biophys Acta (BBA) Mol Cell Biol Lipids 1841:1716–1724. https://doi.org/10.1016/j.bbalip.2014.09.01910.1016/j.bbalip.2014.09.019 ↗
28. Liu Y, Liu YJ (2008) Biosorption isotherms, kinetics and thermodynamics. Sep Purif Technol 61:229–242. https://doi.org/10.1016/j.seppur.2007.10.00210.1016/j.seppur.2007.10.002 ↗
29. Standard II 10993-4 (2017) ISO 10993-4: biological evaluation of medical devices part 4—selection of tests for interactions with blood. International Organization for Standardization, Geneva
30. Dobrovolskaia MA, Clogston JD, Neun BW, Hall JB, Patri, AK, McNeil SE (2008) Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett 8:2180–2187. https://doi.org/10.1021/nl080561510.1021/nl0805615 ↗
31. Amin K, Dannenfelser R-M (2006) In vitro hemolysis: guidance for the pharmaceutical scientist. J Pharm Sci 95:1173–1176. https://doi.org/10.1002/jps.2062710.1002/jps.20627 ↗
32. Haake A, Nguyen K, Friedman L et al (2020) An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf 19:147–157. https://doi.org/10.1080/14740338.2020.172145610.1080/14740338.2020.1721456 ↗
33. Ghasemi M, Turnbull T, Sebastian S, Kempson I (2021) The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. Int J Mol Sci 22:12827. https://doi.org/10.3390/ijms22231282710.3390/ijms222312827 ↗
34. Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 160:171–177. https://doi.org/10.1016/j.toxlet.2005.07.00110.1016/j.toxlet.2005.07.001 ↗
35. Serrano M (2004) In vitro biocompatibility assessment of poly(epsilon-caprolactone) films using L929 mouse fibroblasts. Biomaterials 25:5603–5611. https://doi.org/10.1016/j.biomaterials.2004.01.03710.1016/j.biomaterials.2004.01.037 ↗
36. Weksler B, Romero IA, Couraud P-O (2013) The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10:16. https://doi.org/10.1186/2045-8118-10-1610.1186/2045-8118-10-16 ↗
37. I. Standard (2009) ISO 10993-5 (2009) Biological evaluation of medical devices. International Organization for Standardization, Geneva
38. Esfandyari-Manesh M, Darvishi B, Ishkuh FA et al (2016) Paclitaxel molecularly imprinted polymer-PEG-folate nanoparticles for targeting anticancer delivery: characterization and cellular cytotoxicity. Mater Sci Eng C 62:626–633. https://doi.org/10.1016/j.msec.2016.01.05910.1016/j.msec.2016.01.059 ↗
39. Marais AD (2019) Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology 51:165–176. https://doi.org/10.1016/j.pathol.2018.11.00210.1016/j.pathol.2018.11.002 ↗
40. Hartl N, Adams F, Merkel OM (2021) From adsorption to covalent bonding: apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood–brain barrier. Adv Ther (Weinh) 4:2000092. https://doi.org/10.1002/adtp.20200009210.1002/adtp.202000092 ↗
41. Song Q, Song H, Xu J et al (2016) Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood-brain barrier penetration and amyloid beta-targeting drug delivery. Mol Pharm 13:3976–3987. https://doi.org/10.1021/acs.molpharmaceut.6b0078110.1021/acs.molpharmaceut.6b00781 ↗
42. Zhou S, Huang Y, Chen Y et al (2020) Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials 235:119795. https://doi.org/10.1016/j.biomaterials.2020.11979510.1016/j.biomaterials.2020.119795 ↗
43. Shiraishi T, Kikuchi T, Fukushi K et al (2005) Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology 30:2154–2161. https://doi.org/10.1038/sj.npp.130075910.1038/sj.npp.1300759 ↗
44. Topal GR, Mészáros M, Porkoláb G et al (2020) ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood–brain barrier. Pharmaceutics 13:38. https://doi.org/10.3390/pharmaceutics1301003810.3390/pharmaceutics13010038 ↗